ワクチン市場：タイプ別、技術タイプ別、適応症別、投与経路別、年齢層別-2024～2030年の世界予測

ワクチン市場規模は2023年に556億6,000万米ドルと推定され、2024年には599億4,000万米ドルに達し、CAGR 7.79％で2030年には941億4,000万米ドルに達すると予測されています。

ワクチンは、病気を引き起こす微生物と効果的に闘う能力を身体の免疫系に装備する生物学的製剤です。免疫反応を刺激し、有害な病原体に対する特異的な防御機構（主に抗体の形）を作り出すことで機能します。世界の感染症罹患率の上昇と世界の予防接種プログラムの増加は、この成長に大きく影響しています。さらに、ワクチン開発に対する政府の積極的な取り組みや政策も市場開拓の原動力となっています。高い開発コスト、長い試験と承認プロセス、製品リコールをめぐる問題、一部の地域での入手の難しさなどが、ワクチン市場の成長に対する課題となっています。ワクチンにおけるアジュバントの統合、治療用ワクチンの開発、ワクチンの受託製造の成長は、市場に大きな成長機会をもたらすと期待されています。

タイプ：特定の疾病予防を目的とした一価ワクチンへの大きな嗜好性

一価ワクチンは、1つの抗原または微生物を標的とし、強力で集中的な免疫反応をもたらします。例えば、麻疹ワクチンは一般的にM-M-R IIの形式で接種され、世界的に普及している一価ワクチンです。このようなワクチンは、単一の疾病が支配的で、特異的な免疫反応を必要とする場合に理想的です。多価ワクチンは、複数の病原体や同じ病原体の株に対する免疫を刺激します。広く普及している多価ワクチンは、ジフテリア、破傷風、百日咳を予防するDTPワクチンです。多価ワクチンは、複数の病気が同時に発生する環境に最適です。一価ワクチンは特定の病気との闘いに優れ、多価ワクチンは広範な予防を提供しますが、どちらのタイプも世界の疾病予防のニーズに対応するために不可欠です。多価ワクチンを作るには、様々な病原体に対する有効性を確保するために、より複雑なプロセスが必要です。とはいえ、公衆衛生の観点からは、その適用範囲の広さは、優れた費用対効果をもたらす可能性があります。

技術タイプ：コンジュゲート型ワクチンの開発が進んでいます。

通常、免疫不全の人に処方される不活化ワクチンは、病原体を中和することで製造されます。生きたまま弱毒化されたウイルスから開発された生きたまま弱毒化されたワクチンは、頑健な免疫系に適した長期間の免疫を記載しています。メッセンジャーRNA（mRNA）ワクチンは新しいタイプのワクチンで、免疫反応を引き起こすためにウイルスのRNAの一部のコピーを使用します。サブユニット、リコンビナント、ポリサッカライド、コンジュゲート・シーマは病原体の一部から作られ、特定のワクチン成分にアレルギーのある人でも利用することができます。トキソイドワクチンは、細菌が産生する毒素から保護するように設計されており、そのような感染症にかかりやすい人に提供されます。ウイルスベクターワクチンは、ウイルス表面にあるタンパク質をコードするDNAを持ち、免疫反応を刺激します。これらのワクチンはそれぞれ感染症の予防に重要な役割を果たしています。主に患者の年齢、免疫状態、アレルギーの素因によって選択されます。新たな開発、共同研究、発売により、このセグメントはさらに充実し、より良い患者ケアの選択肢が提供されています。

適応症：重篤な呼吸器疾患に対するDPTワクチンの必要性の高まり

DPTワクチンは、ジフテリア、百日咳、破傷風を予防するために接種されます。通常、生後2ヵ月、4ヵ月、6ヵ月、15～18ヵ月、4～6歳の乳幼児に5回シリーズで接種し、免疫をつける。A型肝炎とB型肝炎を含む肝炎ワクチンは、主に肝臓を侵すこれらのウイルス感染を予防するために接種されます。どちらも通常2回接種し、2回目は1回目の接種から6ヵ月後に行います。ヒトパピローマウイルス（HPV）ワクチンは、子宮頸がんや咽頭がんなど、ある種のがんの原因となることが知られているウイルス感染を予防するために接種します。通常、9～14歳の思春期前の幼児に6ヵ月間隔で2回接種します。インフルエンザワクチンは、通常「インフルエンザの予防接種」として知られ、季節性インフルエンザウイルスから身を守るために毎年接種されます。生後6ヵ月以上のすべての人、特に高齢者や慢性的な健康状態にある人など、重度のインフルエンザ合併症のリスクがある人に推奨されています。麻疹ワクチンは、一般的に麻疹・おたふく風邪・風疹（MMR）ワクチンの一部として接種され、これらの感染力の強いウイルス性疾患から身を守るために、生後12～15ヵ月と4～6歳に2回接種します。髄膜炎菌ワクチンは、髄膜炎や血流感染などの重篤な症状を引き起こす可能性のある細菌感染から守るために接種されます。髄膜炎菌ワクチンは、髄膜炎や血流感染などの重篤な症状を引き起こす可能性のある細菌感染から身を守るために接種されます。流行性耳下腺炎（おたふくかぜ）と風疹（風しん） ワクチン通常、MMRワクチンと麻疹（はしか）の一部として接種されます。免疫を確実にするために小児期に2回接種します。しかし、免疫やワクチン接種歴のない成人でも接種が必要な場合があります。肺炎球菌ワクチンは、肺炎、髄膜炎、血流感染などの肺炎球菌性疾患の原因となる細菌を予防するもので、2歳以下のすべての小児、65歳以上の成人、特定の健康状態にある人を対象としています。ポリオ・ワクチンは、麻痺を引き起こす感染性の高い病気であるポリオ脊髄炎を予防するために接種されます。子どもは通常、2ヶ月、4ヶ月、6～18ヶ月、4～6歳の4回接種します。ロタウイルスワクチンは、乳幼児に重度の下痢を引き起こすウイルス感染症を予防します。通常、生後6ヵ月間に2～3回に分けて経口接種します。水痘ワクチンは、感染力の強い水痘を予防するために接種します。通常2回接種で、1回目は12～15ヵ月、2回目は4～6歳に接種します。

投与経路：免疫反応をより長く持続させるため、経口投与の採用が増加ワクチン

ワクチンの投与方法としては、筋肉内投与と皮下投与が最も一般的です。この投与経路により、ワクチンは筋肉内や皮下に保持され、効率的な免疫応答が促進されます。経口投与は、注射針による投与が好ましくない場合や実用的でない場合によく用いられる方法です。ロタウイルス、ポリオ（OPV）、コレラなどの経口投与は効果的であり、投与が容易であることが証明されています。どちらの投与経路にも、筋肉内投与や皮下投与では迅速な免疫、経口投与では針を使わない利便性など、独自の利点があります。しかし、筋肉注射や皮下注射では痛みや針を刺す傷害、経口ワクチンでは胃腸の状態による制限など、それぞれに欠点があります。ワクチンの選択は、個々のワクチン、レシピエント、医療環境に依存します。非侵襲的なワクチン接種方法の調査は、業界の研究とパートナーシップを促進すると予想されます。

年齢層：HPVワクチンの有用性向上により、予防手段として小児用ワクチンの採用が拡大

18歳以上の成人人口がワクチン市場の大部分を占める。このグループは主に、免疫力を高め、疾病を予防し、旅行用予防接種のニーズを満たすためにワクチンを必要としています。ワクチン市場の小児部門は、18歳以下の小児に焦点を当てています。必要な予防接種、疾病予防、最高医療勧告の遵守が主にこのカテゴリーを牽引しています。成人のワクチン市場は予防とメンテナンスに優れている一方、小児部門は基本的に予防に重点を置いています。

地域別洞察

アジア太平洋では、中国、インド、日本などの堅調な経済が、人口密度が高く感染症の流行が多いため包括的な予防接種が必要となり、ワクチン市場で著しい成長を示しています。米国やカナダなどの南北アメリカでは、人口構成や広範な公衆衛生インフラにより、ワクチンに対するニーズが高いです。ワクチンの研究開発（R&D）への多額の投資、最近の特許、イニシアチブがさらに成長を後押ししています。多様な経済景観を持つ欧州、中東、アフリカ地域では、消費者の行動も様々です。医療制度が充実している欧州連合（EU）では、大規模な予防接種プログラムが必要です。中東・アフリカは市場成長の大きな可能性を秘めています。2022年のインド血清研究所とアフリカ・ワクチン取得トラスト（Africa Vaccine Acquisition Trust）によるCOVID-19の供給協力のような取り組みは、この情勢を形成する極めて重要な変化です。

FPNVポジショニングマトリックス

FPNVポジショニングマトリックスはワクチン市場を評価する上で極めて重要です。事業戦略や製品満足度に関連する主要指標を調査し、ベンダーの包括的な評価を記載しています。この綿密な分析により、ユーザーは各自の要件に沿った十分な情報に基づいた意思決定を行うことができます。評価に基づき、ベンダーは成功の度合いが異なる4つの象限に分類されます。フォアフロント（F）、パスファインダー（P）、ニッチ（N）、バイタル（V）です。

市場シェア分析

市場シェア分析は、ワクチン市場におけるベンダーの現状について、洞察に満ちた詳細な調査を提供する包括的なツールです。全体的な収益、顧客基盤、その他の主要指標についてベンダーの貢献度を綿密に比較・分析することで、企業の業績や市場シェア争いの際に直面する課題について理解を深めることができます。さらに、この分析により、調査対象基準年に観察された累積、断片化の優位性、合併の特徴などの要因を含む、このセグメントの競合特性に関する貴重な考察が得られます。このような詳細レベルの拡大により、ベンダーはより多くの情報に基づいた意思決定を行い、市場で競争優位に立つための効果的な戦略を考案することができます。

本レポートは、以下の側面に関する貴重な洞察を提供しています。

1.市場の浸透度：主要企業が提供する市場に関する包括的な情報を提示しています。

2.市場の開拓度：有利な新興市場を深く掘り下げ、成熟市場セグメントにおける浸透度を分析しています。

3.市場の多様化：新製品の発売、未開拓の地域、最近の開発、投資に関する詳細な情報を記載しています。

4.競合の評価と情報：市場シェア、戦略、製品、認証、規制状況、特許状況、主要企業の製造能力などを網羅的に評価します。

5.製品開発とイノベーション：将来の技術、研究開発活動、画期的な製品開発に関する知的洞察を記載しています。

本レポートは、以下のような主要な質問に対応しています。

1.ワクチン市場の市場規模と予測は？

2.ワクチン市場の予測期間中に投資を検討すべき製品、用途は何か？

3.ワクチン市場の技術動向と規制枠組みは？

4.ワクチン市場における主要ベンダーの市場シェアは？

5.ワクチン市場への参入に適した形態や戦略的手段は？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • 世界的に感染症の発生率が上昇
    • ワクチン開発に対する政府の好ましい取り組みと政策
    • 世界中で予防接種への関心が高まる
  • 抑制要因
    • 開発コストが高く、テストと承認のプロセスが長い
  • 機会
    • ワクチンにおけるアジュバントの統合と治療ワクチンの開発
    • ワクチンの契約製造の成長
  • 課題
    • 一部の地域で製品リコールや入手困難が発生
• 市場セグメンテーション分析
  • タイプ：特定の疾患予防のための一価ワクチンの大幅な好み
  • 技術タイプ：実行可能な代替手段としての共役ワクチンの開発の高まり
  • 適応症：重篤な呼吸器疾患の予防のためのDPTワクチンの需要の高まり
  • 投与経路：免疫反応をより長く持続させるために経口投与の採用を増やす
  • 年齢層：HPVワクチンの有用性の高まりにより、予防手段としての小児ワクチンの採用が拡大
• 市場ディスラプション分析
• ポーターのファイブフォース分析
• バリューチェーンとクリティカルパス分析
• 価格分析
• 技術分析
• 特許分析
• 貿易分析
• 規制枠組みの分析

第6章 ワクチン市場：タイプ別

• イントロダクション
• 一価ワクチン
• 多価ワクチン

第7章 ワクチン市場：技術タイプ別

• イントロダクション
• 無効化されたワクチン
• ライブ減衰ワクチン
• メッセンジャーRNA（mRNA）ワクチン
• サブユニット、組み換え、多糖類、コンジュゲートワクチン
• トキソイドワクチン
• ウイルスベクターワクチン

第8章 ワクチン市場：適応症別

• イントロダクション
• 二酸化ケイ素
• 肝炎
• ヒトパピローマウイルス
• インフルエンザ
• 麻疹
• 髄膜炎菌感染症
• おたふく風邪と風疹
• 肺炎球菌感染症
• ポリオ
• ロタウイルス
• 水痘

第9章 ワクチン市場：投与経路別

• イントロダクション
• 筋肉内と皮下
• 経口

第10章 ワクチン市場：年齢層別

• イントロダクション
• 成人
• 小児

第11章 南北アメリカのワクチン市場

• イントロダクション
• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第12章 アジア太平洋のワクチン市場

• イントロダクション
• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第13章 欧州・中東・アフリカのワクチン市場

• イントロダクション
• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第14章 競合情勢

• 市場シェア分析、2023年
• FPNVポジショニングマトリックス、2023年
• 競合シナリオ分析
• 戦略分析と提言

第15章 競合ポートフォリオ

• 主要企業プロファイル
• 主要製品ポートフォリオ

LIST OF FIGURES

• FIGURE 1. VACCINES MARKET RESEARCH PROCESS
• FIGURE 2. VACCINES MARKET SIZE, 2023 VS 2030
• FIGURE 3. GLOBAL VACCINES MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. GLOBAL VACCINES MARKET SIZE, BY REGION, 2023 VS 2030 (%)
• FIGURE 5. GLOBAL VACCINES MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 6. VACCINES MARKET DYNAMICS
• FIGURE 7. GLOBAL VACCINES MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
• FIGURE 8. GLOBAL VACCINES MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 9. GLOBAL VACCINES MARKET SIZE, BY TECHNOLOGY TYPE, 2023 VS 2030 (%)
• FIGURE 10. GLOBAL VACCINES MARKET SIZE, BY TECHNOLOGY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 11. GLOBAL VACCINES MARKET SIZE, BY INDICATION, 2023 VS 2030 (%)
• FIGURE 12. GLOBAL VACCINES MARKET SIZE, BY INDICATION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 13. GLOBAL VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2030 (%)
• FIGURE 14. GLOBAL VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 15. GLOBAL VACCINES MARKET SIZE, BY AGE GROUP, 2023 VS 2030 (%)
• FIGURE 16. GLOBAL VACCINES MARKET SIZE, BY AGE GROUP, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 17. AMERICAS VACCINES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 18. AMERICAS VACCINES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 19. UNITED STATES VACCINES MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 20. UNITED STATES VACCINES MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 21. ASIA-PACIFIC VACCINES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 22. ASIA-PACIFIC VACCINES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 23. EUROPE, MIDDLE EAST & AFRICA VACCINES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 24. EUROPE, MIDDLE EAST & AFRICA VACCINES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 25. VACCINES MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 26. VACCINES MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. VACCINES MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL VACCINES MARKET SIZE, 2018-2023 (USD MILLION)
• TABLE 4. GLOBAL VACCINES MARKET SIZE, 2024-2030 (USD MILLION)
• TABLE 5. GLOBAL VACCINES MARKET SIZE, BY REGION, 2018-2023 (USD MILLION)
• TABLE 6. GLOBAL VACCINES MARKET SIZE, BY REGION, 2024-2030 (USD MILLION)
• TABLE 7. GLOBAL VACCINES MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
• TABLE 8. GLOBAL VACCINES MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
• TABLE 9. GLOBAL VACCINES MARKET SIZE, BY MONOVALENT VACCINE, BY REGION, 2018-2023 (USD MILLION)
• TABLE 10. GLOBAL VACCINES MARKET SIZE, BY MONOVALENT VACCINE, BY REGION, 2024-2030 (USD MILLION)
• TABLE 11. GLOBAL VACCINES MARKET SIZE, BY MULTIVALENT VACCINE, BY REGION, 2018-2023 (USD MILLION)
• TABLE 12. GLOBAL VACCINES MARKET SIZE, BY MULTIVALENT VACCINE, BY REGION, 2024-2030 (USD MILLION)
• TABLE 13. GLOBAL VACCINES MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2023 (USD MILLION)
• TABLE 14. GLOBAL VACCINES MARKET SIZE, BY TECHNOLOGY TYPE, 2024-2030 (USD MILLION)
• TABLE 15. GLOBAL VACCINES MARKET SIZE, BY INACTIVATED VACCINES, BY REGION, 2018-2023 (USD MILLION)
• TABLE 16. GLOBAL VACCINES MARKET SIZE, BY INACTIVATED VACCINES, BY REGION, 2024-2030 (USD MILLION)
• TABLE 17. GLOBAL VACCINES MARKET SIZE, BY LIVE-ATTENUATED VACCINES, BY REGION, 2018-2023 (USD MILLION)
• TABLE 18. GLOBAL VACCINES MARKET SIZE, BY LIVE-ATTENUATED VACCINES, BY REGION, 2024-2030 (USD MILLION)
• TABLE 19. GLOBAL VACCINES MARKET SIZE, BY MESSENGER RNA (MRNA) VACCINES, BY REGION, 2018-2023 (USD MILLION)
• TABLE 20. GLOBAL VACCINES MARKET SIZE, BY MESSENGER RNA (MRNA) VACCINES, BY REGION, 2024-2030 (USD MILLION)
• TABLE 21. GLOBAL VACCINES MARKET SIZE, BY SUBUNIT, RECOMBINANT, POLYSACCHARIDE, & CONJUGATE VACCINES, BY REGION, 2018-2023 (USD MILLION)
• TABLE 22. GLOBAL VACCINES MARKET SIZE, BY SUBUNIT, RECOMBINANT, POLYSACCHARIDE, & CONJUGATE VACCINES, BY REGION, 2024-2030 (USD MILLION)
• TABLE 23. GLOBAL VACCINES MARKET SIZE, BY TOXOID VACCINES, BY REGION, 2018-2023 (USD MILLION)
• TABLE 24. GLOBAL VACCINES MARKET SIZE, BY TOXOID VACCINES, BY REGION, 2024-2030 (USD MILLION)
• TABLE 25. GLOBAL VACCINES MARKET SIZE, BY VIRAL VECTOR VACCINES, BY REGION, 2018-2023 (USD MILLION)
• TABLE 26. GLOBAL VACCINES MARKET SIZE, BY VIRAL VECTOR VACCINES, BY REGION, 2024-2030 (USD MILLION)
• TABLE 27. GLOBAL VACCINES MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
• TABLE 28. GLOBAL VACCINES MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
• TABLE 29. GLOBAL VACCINES MARKET SIZE, BY DPT, BY REGION, 2018-2023 (USD MILLION)
• TABLE 30. GLOBAL VACCINES MARKET SIZE, BY DPT, BY REGION, 2024-2030 (USD MILLION)
• TABLE 31. GLOBAL VACCINES MARKET SIZE, BY HEPATITIS, BY REGION, 2018-2023 (USD MILLION)
• TABLE 32. GLOBAL VACCINES MARKET SIZE, BY HEPATITIS, BY REGION, 2024-2030 (USD MILLION)
• TABLE 33. GLOBAL VACCINES MARKET SIZE, BY HUMAN PAPILLOMAVIRUS, BY REGION, 2018-2023 (USD MILLION)
• TABLE 34. GLOBAL VACCINES MARKET SIZE, BY HUMAN PAPILLOMAVIRUS, BY REGION, 2024-2030 (USD MILLION)
• TABLE 35. GLOBAL VACCINES MARKET SIZE, BY INFLUENZA, BY REGION, 2018-2023 (USD MILLION)
• TABLE 36. GLOBAL VACCINES MARKET SIZE, BY INFLUENZA, BY REGION, 2024-2030 (USD MILLION)
• TABLE 37. GLOBAL VACCINES MARKET SIZE, BY MEASLES, BY REGION, 2018-2023 (USD MILLION)
• TABLE 38. GLOBAL VACCINES MARKET SIZE, BY MEASLES, BY REGION, 2024-2030 (USD MILLION)
• TABLE 39. GLOBAL VACCINES MARKET SIZE, BY MENINGOCOCCAL DISEASE, BY REGION, 2018-2023 (USD MILLION)
• TABLE 40. GLOBAL VACCINES MARKET SIZE, BY MENINGOCOCCAL DISEASE, BY REGION, 2024-2030 (USD MILLION)
• TABLE 41. GLOBAL VACCINES MARKET SIZE, BY MUMPS & RUBELLA, BY REGION, 2018-2023 (USD MILLION)
• TABLE 42. GLOBAL VACCINES MARKET SIZE, BY MUMPS & RUBELLA, BY REGION, 2024-2030 (USD MILLION)
• TABLE 43. GLOBAL VACCINES MARKET SIZE, BY PNEUMOCOCCAL DISEASE, BY REGION, 2018-2023 (USD MILLION)
• TABLE 44. GLOBAL VACCINES MARKET SIZE, BY PNEUMOCOCCAL DISEASE, BY REGION, 2024-2030 (USD MILLION)
• TABLE 45. GLOBAL VACCINES MARKET SIZE, BY POLIO, BY REGION, 2018-2023 (USD MILLION)
• TABLE 46. GLOBAL VACCINES MARKET SIZE, BY POLIO, BY REGION, 2024-2030 (USD MILLION)
• TABLE 47. GLOBAL VACCINES MARKET SIZE, BY ROTAVIRUS, BY REGION, 2018-2023 (USD MILLION)
• TABLE 48. GLOBAL VACCINES MARKET SIZE, BY ROTAVIRUS, BY REGION, 2024-2030 (USD MILLION)
• TABLE 49. GLOBAL VACCINES MARKET SIZE, BY VARICELLA, BY REGION, 2018-2023 (USD MILLION)
• TABLE 50. GLOBAL VACCINES MARKET SIZE, BY VARICELLA, BY REGION, 2024-2030 (USD MILLION)
• TABLE 51. GLOBAL VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
• TABLE 52. GLOBAL VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
• TABLE 53. GLOBAL VACCINES MARKET SIZE, BY INTRAMUSCULAR & SUBCUTANEOUS, BY REGION, 2018-2023 (USD MILLION)
• TABLE 54. GLOBAL VACCINES MARKET SIZE, BY INTRAMUSCULAR & SUBCUTANEOUS, BY REGION, 2024-2030 (USD MILLION)
• TABLE 55. GLOBAL VACCINES MARKET SIZE, BY ORAL, BY REGION, 2018-2023 (USD MILLION)
• TABLE 56. GLOBAL VACCINES MARKET SIZE, BY ORAL, BY REGION, 2024-2030 (USD MILLION)
• TABLE 57. GLOBAL VACCINES MARKET SIZE, BY AGE GROUP, 2018-2023 (USD MILLION)
• TABLE 58. GLOBAL VACCINES MARKET SIZE, BY AGE GROUP, 2024-2030 (USD MILLION)
• TABLE 59. GLOBAL VACCINES MARKET SIZE, BY ADULTS, BY REGION, 2018-2023 (USD MILLION)
• TABLE 60. GLOBAL VACCINES MARKET SIZE, BY ADULTS, BY REGION, 2024-2030 (USD MILLION)
• TABLE 61. GLOBAL VACCINES MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2023 (USD MILLION)
• TABLE 62. GLOBAL VACCINES MARKET SIZE, BY PEDIATRIC, BY REGION, 2024-2030 (USD MILLION)
• TABLE 63. AMERICAS VACCINES MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
• TABLE 64. AMERICAS VACCINES MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
• TABLE 65. AMERICAS VACCINES MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2023 (USD MILLION)
• TABLE 66. AMERICAS VACCINES MARKET SIZE, BY TECHNOLOGY TYPE, 2024-2030 (USD MILLION)
• TABLE 67. AMERICAS VACCINES MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
• TABLE 68. AMERICAS VACCINES MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
• TABLE 69. AMERICAS VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
• TABLE 70. AMERICAS VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
• TABLE 71. AMERICAS VACCINES MARKET SIZE, BY AGE GROUP, 2018-2023 (USD MILLION)
• TABLE 72. AMERICAS VACCINES MARKET SIZE, BY AGE GROUP, 2024-2030 (USD MILLION)
• TABLE 73. AMERICAS VACCINES MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
• TABLE 74. AMERICAS VACCINES MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
• TABLE 75. ARGENTINA VACCINES MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
• TABLE 76. ARGENTINA VACCINES MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
• TABLE 77. ARGENTINA VACCINES MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2023 (USD MILLION)
• TABLE 78. ARGENTINA VACCINES MARKET SIZE, BY TECHNOLOGY TYPE, 2024-2030 (USD MILLION)
• TABLE 79. ARGENTINA VACCINES MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
• TABLE 80. ARGENTINA VACCINES MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
• TABLE 81. ARGENTINA VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
• TABLE 82. ARGENTINA VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
• TABLE 83. ARGENTINA VACCINES MARKET SIZE, BY AGE GROUP, 2018-2023 (USD MILLION)
• TABLE 84. ARGENTINA VACCINES MARKET SIZE, BY AGE GROUP, 2024-2030 (USD MILLION)
• TABLE 85. BRAZIL VACCINES MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
• TABLE 86. BRAZIL VACCINES MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
• TABLE 87. BRAZIL VACCINES MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2023 (USD MILLION)
• TABLE 88. BRAZIL VACCINES MARKET SIZE, BY TECHNOLOGY TYPE, 2024-2030 (USD MILLION)
• TABLE 89. BRAZIL VACCINES MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
• TABLE 90. BRAZIL VACCINES MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
• TABLE 91. BRAZIL VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
• TABLE 92. BRAZIL VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
• TABLE 93. BRAZIL VACCINES MARKET SIZE, BY AGE GROUP, 2018-2023 (USD MILLION)
• TABLE 94. BRAZIL VACCINES MARKET SIZE, BY AGE GROUP, 2024-2030 (USD MILLION)
• TABLE 95. CANADA VACCINES MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
• TABLE 96. CANADA VACCINES MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
• TABLE 97. CANADA VACCINES MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2023 (USD MILLION)
• TABLE 98. CANADA VACCINES MARKET SIZE, BY TECHNOLOGY TYPE, 2024-2030 (USD MILLION)
• TABLE 99. CANADA VACCINES MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
• TABLE 100. CANADA VACCINES MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
• TABLE 101. CANADA VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
• TABLE 102. CANADA VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
• TABLE 103. CANADA VACCINES MARKET SIZE, BY AGE GROUP, 2018-2023 (USD MILLION)
• TABLE 104. CANADA VACCINES MARKET SIZE, BY AGE GROUP, 2024-2030 (USD MILLION)
• TABLE 105. MEXICO VACCINES MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
• TABLE 106. MEXICO VACCINES MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
• TABLE 107. MEXICO VACCINES MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2023 (USD MILLION)
• TABLE 108. MEXICO VACCINES MARKET SIZE, BY TECHNOLOGY TYPE, 2024-2030 (USD MILLION)
• TABLE 109. MEXICO VACCINES MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
• TABLE 110. MEXICO VACCINES MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
• TABLE 111. MEXICO VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
• TABLE 112. MEXICO VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
• TABLE 113. MEXICO VACCINES MARKET SIZE, BY AGE GROUP, 2018-2023 (USD MILLION)
• TABLE 114. MEXICO VACCINES MARKET SIZE, BY AGE GROUP, 2024-2030 (USD MILLION)
• TABLE 115. UNITED STATES VACCINES MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
• TABLE 116. UNITED STATES VACCINES MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
• TABLE 117. UNITED STATES VACCINES MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2023 (USD MILLION)
• TABLE 118. UNITED STATES VACCINES MARKET SIZE, BY TECHNOLOGY TYPE, 2024-2030 (USD MILLION)
• TABLE 119. UNITED STATES VACCINES MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
• TABLE 120. UNITED STATES VACCINES MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
• TABLE 121. UNITED STATES VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
• TABLE 122. UNITED STATES VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
• TABLE 123. UNITED STATES VACCINES MARKET SIZE, BY AGE GROUP, 2018-2023 (USD MILLION)
• TABLE 124. UNITED STATES VACCINES MARKET SIZE, BY AGE GROUP, 2024-2030 (USD MILLION)
• TABLE 125. UNITED STATES VACCINES MARKET SIZE, BY STATE, 2018-2023 (USD MILLION)
• TABLE 126. UNITED STATES VACCINES MARKET SIZE, BY STATE, 2024-2030 (USD MILLION)
• TABLE 127. ASIA-PACIFIC VACCINES MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
• TABLE 128. ASIA-PACIFIC VACCINES MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
• TABLE 129. ASIA-PACIFIC VACCINES MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2023 (USD MILLION)
• TABLE 130. ASIA-PACIFIC VACCINES MARKET SIZE, BY TECHNOLOGY TYPE, 2024-2030 (USD MILLION)
• TABLE 131. ASIA-PACIFIC VACCINES MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
• TABLE 132. ASIA-PACIFIC VACCINES MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
• TABLE 133. ASIA-PACIFIC VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
• TABLE 134. ASIA-PACIFIC VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
• TABLE 135. ASIA-PACIFIC VACCINES MARKET SIZE, BY AGE GROUP, 2018-2023 (USD MILLION)
• TABLE 136. ASIA-PACIFIC VACCINES MARKET SIZE, BY AGE GROUP, 2024-2030 (USD MILLION)
• TABLE 137. ASIA-PACIFIC VACCINES MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
• TABLE 138. ASIA-PACIFIC VACCINES MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
• TABLE 139. AUSTRALIA VACCINES MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
• TABLE 140. AUSTRALIA VACCINES MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
• TABLE 141. AUSTRALIA VACCINES MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2023 (USD MILLION)
• TABLE 142. AUSTRALIA VACCINES MARKET SIZE, BY TECHNOLOGY TYPE, 2024-2030 (USD MILLION)
• TABLE 143. AUSTRALIA VACCINES MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
• TABLE 144. AUSTRALIA VACCINES MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
• TABLE 145. AUSTRALIA VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
• TABLE 146. AUSTRALIA VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
• TABLE 147. AUSTRALIA VACCINES MARKET SIZE, BY AGE GROUP, 2018-2023 (USD MILLION)
• TABLE 148. AUSTRALIA VACCINES MARKET SIZE, BY AGE GROUP, 2024-2030 (USD MILLION)
• TABLE 149. CHINA VACCINES MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
• TABLE 150. CHINA VACCINES MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
• TABLE 151. CHINA VACCINES MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2023 (USD MILLION)
• TABLE 152. CHINA VACCINES MARKET SIZE, BY TECHNOLOGY TYPE, 2024-2030 (USD MILLION)
• TABLE 153. CHINA VACCINES MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
• TABLE 154. CHINA VACCINES MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
• TABLE 155. CHINA VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
• TABLE 156. CHINA VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
• TABLE 157. CHINA VACCINES MARKET SIZE, BY AGE GROUP, 2018-2023 (USD MILLION)
• TABLE 158. CHINA VACCINES MARKET SIZE, BY AGE GROUP, 2024-2030 (USD MILLION)
• TABLE 159. INDIA VACCINES MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
• TABLE 160. INDIA VACCINES MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
• TABLE 161. INDIA VACCINES MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2023 (USD MILLION)
• TABLE 162. INDIA VACCINES MARKET SIZE, BY TECHNOLOGY TYPE, 2024-2030 (USD MILLION)
• TABLE 163. INDIA VACCINES MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
• TABLE 164. INDIA VACCINES MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
• TABLE 165. INDIA VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
• TABLE 166. INDIA VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
• TABLE 167. INDIA VACCINES MARKET SIZE, BY AGE GROUP, 2018-2023 (USD MILLION)
• TABLE 168. INDIA VACCINES MARKET SIZE, BY AGE GROUP, 2024-2030 (USD MILLION)
• TABLE 169. INDONESIA VACCINES MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
• TABLE 170. INDONESIA VACCINES MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
• TABLE 171. INDONESIA VACCINES MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2023 (USD MILLION)
• TABLE 172. INDONESIA VACCINES MARKET SIZE, BY TECHNOLOGY TYPE, 2024-2030 (USD MILLION)
• TABLE 173. INDONESIA VACCINES MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
• TABLE 174. INDONESIA VACCINES MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
• TABLE 175. INDONESIA VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
• TABLE 176. INDONESIA VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
• TABLE 177. INDONESIA VACCINES MARKET SIZE, BY AGE GROUP, 2018-2023 (USD MILLION)
• TABLE 178. INDONESIA VACCINES MARKET SIZE, BY AGE GROUP, 2024-2030 (USD MILLION)
• TABLE 179. JAPAN VACCINES MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
• TABLE 180. JAPAN VACCINES MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
• TABLE 181. JAPAN VACCINES MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2023 (USD MILLION)
• TABLE 182. JAPAN VACCINES MARKET SIZE, BY TECHNOLOGY TYPE, 2024-2030 (USD MILLION)
• TABLE 183. JAPAN VACCINES MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
• TABLE 184. JAPAN VACCINES MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
• TABLE 185. JAPAN VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
• TABLE 186. JAPAN VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
• TABLE 187. JAPAN VACCINES MARKET SIZE, BY AGE GROUP, 2018-2023 (USD MILLION)
• TABLE 188. JAPAN VACCINES MARKET SIZE, BY AGE GROUP, 2024-2030 (USD MILLION)
• TABLE 189. MALAYSIA VACCINES MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
• TABLE 190. MALAYSIA VACCINES MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
• TABLE 191. MALAYSIA VACCINES MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2023 (USD MILLION)
• TABLE 192. MALAYSIA VACCINES MARKET SIZE, BY TECHNOLOGY TYPE, 2024-2030 (USD MILLION)
• TABLE 193. MALAYSIA VACCINES MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
• TABLE 194. MALAYSIA VACCINES MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
• TABLE 195. MALAYSIA VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
• TABLE 196. MALAYSIA VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
• TABLE 197. MALAYSIA VACCINES MARKET SIZE, BY AGE GROUP, 2018-2023 (USD MILLION)
• TABLE 198. MALAYSIA VACCINES MARKET SIZE, BY AGE GROUP, 2024-2030 (USD MILLION)
• TABLE 199. PHILIPPINES VACCINES MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
• TABLE 200. PHILIPPINES VACCINES MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
• TABLE 201. PHILIPPINES VACCINES MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2023 (USD MILLION)
• TABLE 202. PHILIPPINES VACCINES MARKET SIZE, BY TECHNOLOGY TYPE, 2024-2030 (USD MILLION)
• TABLE 203. PHILIPPINES VACCINES MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
• TABLE 204. PHILIPPINES VACCINES MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
• TABLE 205. PHILIPPINES VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
• TABLE 206. PHILIPPINES VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
• TABLE 207. PHILIPPINES VACCINES MARKET SIZE, BY AGE GROUP, 2018-2023 (USD MILLION)
• TABLE 208. PHILIPPINES VACCINES MARKET SIZE, BY AGE GROUP, 2024-2030 (USD MILLION)
• TABLE 209. SINGAPORE VACCINES MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
• TABLE 210. SINGAPORE VACCINES MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
• TABLE 211. SINGAPORE VACCINES MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2023 (USD MILLION)
• TABLE 212. SINGAPORE VACCINES MARKET SIZE, BY TECHNOLOGY TYPE, 2024-2030 (USD MILLION)
• TABLE 213. SINGAPORE VACCINES MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
• TABLE 214. SINGAPORE VACCINES MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
• TABLE 215. SINGAPORE VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
• TABLE 216. SINGAPORE VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
• TABLE 217. SINGAPORE VACCINES MARKET SIZE, BY AGE GROUP, 2018-2023 (USD MILLION)
• TABLE 218. SINGAPORE VACCINES MARKET SIZE, BY AGE GROUP, 2024-2030 (USD MILLION)
• TABLE 219. SOUTH KOREA VACCINES MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
• TABLE 220. SOUTH KOREA VACCINES MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
• TABLE 221. SOUTH KOREA VACCINES MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2023 (USD MILLION)
• TABLE 222. SOUTH KOREA VACCINES MARKET SIZE, BY TECHNOLOGY TYPE, 2024-2030 (USD MILLION)
• TABLE 223. SOUTH KOREA VACCINES MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
• TABLE 224. SOUTH KOREA VACCINES MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
• TABLE 225. SOUTH KOREA VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
• TABLE 226. SOUTH KOREA VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
• TABLE 227. SOUTH KOREA VACCINES MARKET SIZE, BY AGE GROUP, 2018-2023 (USD MILLION)
• TABLE 228. SOUTH KOREA VACCINES MARKET SIZE, BY AGE GROUP, 2024-2030 (USD MILLION)
• TABLE 229. TAIWAN VACCINES MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
• TABLE 230. TAIWAN VACCINES MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
• TABLE 231. TAIWAN VACCINES MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2023 (USD MILLION)
• TABLE 232. TAIWAN VACCINES MARKET SIZE, BY TECHNOLOGY TYPE, 2024-2030 (USD MILLION)
• TABLE 233. TAIWAN VACCINES MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
• TABLE 234. TAIWAN VACCINES MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
• TABLE 235. TAIWAN VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
• TABLE 236. TAIWAN VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
• TABLE 237. TAIWAN VACCINES MARKET SIZE, BY AGE GROUP, 2018-2023 (USD MILLION)
• TABLE 238. TAIWAN VACCINES MARKET SIZE, BY AGE GROUP, 2024-2030 (USD MILLION)
• TABLE 239. THAILAND VACCINES MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
• TABLE 240. THAILAND VACCINES MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
• TABLE 241. THAILAND VACCINES MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2023 (USD MILLION)
• TABLE 242. THAILAND VACCINES MARKET SIZE, BY TECHNOLOGY TYPE, 2024-2030 (USD MILLION)
• TABLE 243. THAILAND VACCINES MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
• TABLE 244. THAILAND VACCINES MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
• TABLE 245. THAILAND VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
• TABLE 246. THAILAND VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
• TABLE 247. THAILAND VACCINES MARKET SIZE, BY AGE GROUP, 2018-2023 (USD MILLION)
• TABLE 248. THAILAND VACCINES MARKET SIZE, BY AGE GROUP, 2024-2030 (USD MILLION)
• TABLE 249. VIETNAM VACCINES MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
• TABLE 250. VIETNAM VACCINES MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
• TABLE 251. VIETNAM VACCINES MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2023 (USD MILLION)
• TABLE 252. VIETNAM VACCINES MARKET SIZE, BY TECHNOLOGY TYPE, 2024-2030 (USD MILLION)
• TABLE 253. VIETNAM VACCINES MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
• TABLE 254. VIETNAM VACCINES MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
• TABLE 255. VIETNAM VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
• TABLE 256. VIETNAM VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
• TABLE 257. VIETNAM VACCINES MARKET SIZE, BY AGE GROUP, 2018-2023 (USD MILLION)
• TABLE 258. VIETNAM VACCINES MARKET SIZE, BY AGE GROUP, 2024-2030 (USD MILLION)
• TABLE 259. EUROPE, MIDDLE EAST & AFRICA VACCINES MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
• TABLE 260. EUROPE, MIDDLE EAST & AFRICA VACCINES MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
• TABLE 261. EUROPE, MIDDLE EAST & AFRICA VACCINES MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2023 (USD MILLION)
• TABLE 262. EUROPE, MIDDLE EAST & AFRICA VACCINES MARKET SIZE, BY TECHNOLOGY TYPE, 2024-2030 (USD MILLION)
• TABLE 263. EUROPE, MIDDLE EAST & AFRICA VACCINES MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
• TABLE 264. EUROPE, MIDDLE EAST & AFRICA VACCINES MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
• TABLE 265. EUROPE, MIDDLE EAST & AFRICA VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
• TABLE 266. EUROPE, MIDDLE EAST & AFRICA VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
• TABLE 267. EUROPE, MIDDLE EAST & AFRICA VACCINES MARKET SIZE, BY AGE GROUP, 2018-2023 (USD MILLION)
• TABLE 268. EUROPE, MIDDLE EAST & AFRICA VACCINES MARKET SIZE, BY AGE GROUP, 2024-2030 (USD MILLION)
• TABLE 269. EUROPE, MIDDLE EAST & AFRICA VACCINES MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
• TABLE 270. EUROPE, MIDDLE EAST & AFRICA VACCINES MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
• TABLE 271. DENMARK VACCINES MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
• TABLE 272. DENMARK VACCINES MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
• TABLE 273. DENMARK VACCINES MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2023 (USD MILLION)
• TABLE 274. DENMARK VACCINES MARKET SIZE, BY TECHNOLOGY TYPE, 2024-2030 (USD MILLION)
• TABLE 275. DENMARK VACCINES MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
• TABLE 276. DENMARK VACCINES MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
• TABLE 277. DENMARK VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
• TABLE 278. DENMARK VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
• TABLE 279. DENMARK VACCINES MARKET SIZE, BY AGE GROUP, 2018-2023 (USD MILLION)
• TABLE 280. DENMARK VACCINES MARKET SIZE, BY AGE GROUP, 2024-2030 (USD MILLION)
• TABLE 281. EGYPT VACCINES MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
• TABLE 282. EGYPT VACCINES MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
• TABLE 283. EGYPT VACCINES MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2023 (USD MILLION)
• TABLE 284. EGYPT VACCINES MARKET SIZE, BY TECHNOLOGY TYPE, 2024-2030 (USD MILLION)
• TABLE 285. EGYPT VACCINES MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
• TABLE 286. EGYPT VACCINES MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
• TABLE 287. EGYPT VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
• TABLE 288. EGYPT VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
• TABLE 289. EGYPT VACCINES MARKET SIZE, BY AGE GROUP, 2018-2023 (USD MILLION)
• TABLE 290. EGYPT VACCINES MARKET SIZE, BY AGE GROUP, 2024-2030 (USD MILLION)
• TABLE 291. FINLAND VACCINES MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
• TABLE 292. FINLAND VACCINES MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
• TABLE 293. FINLAND VACCINES MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2023 (USD MILLION)
• TABLE 294. FINLAND VACCINES MARKET SIZE, BY TECHNOLOGY TYPE, 2024-2030 (USD MILLION)
• TABLE 295. FINLAND VACCINES MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
• TABLE 296. FINLAND VACCINES MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
• TABLE 297. FINLAND VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
• TABLE 298. FINLAND VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
• TABLE 299. FINLAND VACCINES MARKET SIZE, BY AGE GROUP, 2018-2023 (USD MILLION)
• TABLE 300. FINLAND VACCINES MARKET SIZE, BY AGE GROUP, 2024-2030 (USD MILLION)
• TABLE 301. FRANCE VACCINES MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
• TABLE 302. FRANCE VACCINES MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
• TABLE 303. FRANCE VACCINES MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2023 (USD MILLION)
• TABLE 304. FRANCE VACCINES MARKET SIZE, BY TECHNOLOGY TYPE, 2024-2030 (USD MILLION)
• TABLE 305. FRANCE VACCINES MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
• TABLE 306. FRANCE VACCINES MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
• TABLE 307. FRANCE VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
• TABLE 308. FRANCE VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
• TABLE 309. FRANCE VACCINES MARKET SIZE, BY AGE GROUP, 2018-2023 (USD MILLION)
• TABLE 310. FRANCE VACCINES MARKET SIZE, BY AGE GROUP, 2024-2030 (USD MILLION)
• TABLE 311. GERMANY VACCINES MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
• TABLE 312. GERMANY VACCINES MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
• TABLE 313. GERMANY VACCINES MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2023 (USD MILLION)
• TABLE 314. GERMANY VACCINES MARKET SIZE, BY TECHNOLOGY TYPE, 2024-2030 (USD MILLION)
• TABLE 315. GERMANY VACCINES MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
• TABLE 316. GERMANY VACCINES MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
• TABLE 317. GERMANY VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
• TABLE 318. GERMANY VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
• TABLE 319. GERMANY VACCINES MARKET SIZE, BY AGE GROUP, 2018-2023 (USD MILLION)
• TABLE 320. GERMANY VACCINES MARKET SIZE, BY AGE GROUP, 2024-2030 (USD MILLION)
• TABLE 321. ISRAEL VACCINES MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
• TABLE 322. ISRAEL VACCINES MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
• TABLE 323. ISRAEL VACCINES MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2023 (USD MILLION)
• TABLE 324. ISRAEL VACCINES MARKET SIZE, BY TECHNOLOGY TYPE, 2024-2030 (USD MILLION)
• TABLE 325. ISRAEL VACCINES MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
• TABLE 326. ISRAEL VACCINES MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
• TABLE 327. ISRAEL VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
• TABLE 328. ISRAEL VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
• TABLE 329. ISRAEL VACCINES MARKET SIZE, BY AGE GROUP, 2018-2023 (USD MILLION)
• TABLE 330. ISRAEL VACCINES MARKET SIZE, BY AGE GROUP, 2024-2030 (USD MILLION)
• TABLE 331. ITALY VACCINES MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
• TABLE 332. ITALY VACCINES MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
• TABLE 333. ITALY VACCINES MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2023 (USD MILLION)
• TABLE 334. ITALY VACCINES MARKET SIZE, BY TECHNOLOGY TYPE, 2024-2030 (USD MILLION)
• TABLE 335. ITALY VACCINES MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
• TABLE 336. ITALY VACCINES MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
• TABLE 337. ITALY VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
• TABLE 338. ITALY VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
• TABLE 339. ITALY VACCINES MARKET SIZE, BY AGE GROUP, 2018-2023 (USD MILLION)
• TABLE 340. ITALY VACCINES MARKET SIZE, BY AGE GROUP, 2024-2030 (USD MILLION)
• TABLE 341. NETHERLANDS VACCINES MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
• TABLE 342. NETHERLANDS VACCINES MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
• TABLE 343. NETHERLANDS VACCINES MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2023 (USD MILLION)
• TABLE 344. NETHERLANDS VACCINES MARKET SIZE, BY TECHNOLOGY TYPE, 2024-2030 (USD MILLION)
• TABLE 345. NETHERLANDS VACCINES MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
• TABLE 346. NETHERLANDS VACCINES MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
• TABLE 347. NETHERLANDS VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
• TABLE 348. NETHERLANDS VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
• TABLE 349. NETHERLANDS VACCINES MARKET SIZE, BY AGE GROUP, 2018-2023 (USD MILLION)
• TABLE 350. NETHERLANDS VACCINES MARKET SIZE, BY AGE GROUP, 2024-2030 (USD MILLION)
• TABLE 351. NIGERIA VACCINES MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
• TABLE 352. NIGERIA VACCINES MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
• TABLE 353. NIGERIA VACCINES MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2023 (USD MILLION)
• TABLE 354. NIGERIA VACCINES MARKET SIZE, BY TECHNOLOGY TYPE, 2024-2030 (USD MILLION)
• TABLE 355. NIGERIA VACCINES MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
• TABLE 356. NIGERIA VACCINES MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
• TABLE 357. NIGERIA VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
• TABLE 358. NIGERIA VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
• TABLE 359. NIGERIA VACCINES MARKET SIZE, BY AGE GROUP, 2018-2023 (USD MILLION)
• TABLE 360. NIGERIA VACCINES MARKET SIZE, BY AGE GROUP, 2024-2030 (USD MILLION)
• TABLE 361. NORWAY VACCINES MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
• TABLE 362. NORWAY VACCINES MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
• TABLE 363. NORWAY VACCINES MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2023 (USD MILLION)
• TABLE 364. NORWAY VACCINES MARKET SIZE, BY TECHNOLOGY TYPE, 2024-2030 (USD MILLION)
• TABLE 365. NORWAY VACCINES MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
• TABLE 366. NORWAY VACCINES MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
• TABLE 367. NORWAY VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
• TABLE 368. NORWAY VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
• TABLE 369. NORWAY VACCINES MARKET SIZE, BY AGE GROUP, 2018-2023 (USD MILLION)
• TABLE 370. NORWAY VACCINES MARKET SIZE, BY AGE GROUP, 2024-2030 (USD MILLION)
• TABLE 371. POLAND VACCINES MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
• TABLE 372. POLAND VACCINES MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
• TABLE 373. POLAND VACCINES MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2023 (USD MILLION)
• TABLE 374. POLAND VACCINES MARKET SIZE, BY TECHNOLOGY TYPE, 2024-2030 (USD MILLION)
• TABLE 375. POLAND VACCINES MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
• TABLE 376. POLAND VACCINES MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
• TABLE 377. POLAND VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
• TABLE 378. POLAND VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
• TABLE 379. POLAND VACCINES MARKET SIZE, BY AGE GROUP, 2018-2023 (USD MILLION)
• TABLE 380. POLAND VACCINES MARKET SIZE, BY AGE GROUP, 2024-2030 (USD MILLION)
• TABLE 381. QATAR VACCINES MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
• TABLE 382. QATAR VACCINES MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
• TABLE 383. QATAR VACCINES MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2023 (USD MILLION)
• TABLE 384. QATAR VACCINES MARKET SIZE, BY TECHNOLOGY TYPE, 2024-2030 (USD MILLION)
• TABLE 385. QATAR VACCINES MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
• TABLE 386. QATAR VACCINES MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
• TABLE 387. QATAR VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
• TABLE 388. QATAR VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
• TABLE 389. QATAR VACCINES MARKET SIZE, BY AGE GROUP, 2018-202

[194 Pages Report] The Vaccines Market size was estimated at USD 55.66 billion in 2023 and expected to reach USD 59.94 billion in 2024, at a CAGR 7.79% to reach USD 94.14 billion by 2030.

Vaccines are biological preparations that equip the body's immune system with the capability to combat disease-causing microbes effectively. They work by stimulating the immune response to generate a specific defense mechanism, predominantly in the form of antibodies, against harmful pathogens. The rising incidence of infectious diseases globally and the rise in immunization programs worldwide significantly influence this growth. Moreover, favorable government initiatives and policies for vaccine development are also driving market growth. High development costs, lengthy testing and approval process issues over product recalls, and inaccessibility in a few regions pose challenges to the growth of the vaccine market. Integration of adjuvants in vaccines, development of therapeutic vaccines, and growth in the contract manufacturing of the vaccines are expected to create significant growth opportunities in the market.

Type: Significant preference for monovalent vaccines for specific disease prevention

Monovalent vaccines target one antigen or microorganism, producing a potent, focused immune response. For instance, the measles vaccine, commonly delivered in the M-M-R II format, is a globally prevalent monovalent vaccine. Such vaccines are ideal when single diseases dominate, requiring a specific immune response. Multivalent vaccines stimulate immunity against multiple pathogens or strains of the same pathogen. A widespread multivalent vaccine is the DTP vaccine, which safeguards against Diphtheria, Tetanus, and Pertussis. Multivalent vaccines are best suited for environments with multiple concurrent diseases. Even though monovalent vaccines excel in combating specific illnesses and multivalent vaccines offer broad-scope protection, both types are indispensable for addressing global disease prevention needs. Crafting multivalent vaccines requires a more intricate process to ensure efficacy against various pathogens. Nevertheless, their vast coverage could present superior, cost-effective advantages from a public health standpoint.

Technology Type: Rising development in the conjugate vaccines as an viable alternative

Inactivated vaccines, typically prescribed for the immune-compromised, are produced by neutralizing a pathogen. Live-attenuated vaccines, developed from a live yet weakened virus, provide prolonged immunity suitable for robust immune systems. Messenger RNA (mRNA) vaccines, a new breed of vaccines, use a copy of a part of the virus's RNA to provoke an immune response. Subunit, recombinant, polysaccharide, and conjugate vaccines are made from a piece of the pathogen that can be utilized by those allergic to certain vaccine components. Toxoid vaccines are designed to protect against bacteria-produced toxins, and are provided to individuals prone to such infections. Viral vector vaccines function by carrying a piece of DNA that codes for a protein found on the virus surface to stimulate an immune response. Each of these types of vaccines plays a crucial role in preventing infectious diseases. The selection depends mainly on the patient's age, immune status, or predisposed allergies. New developments, collaborations, and launches have further enriched this field, providing better patient care options.

Indication: Growing need for DPT vaccine for protection against serious respiratory ailments

The DPT vaccine is administered to protect against diphtheria, pertussis (whooping cough), and tetanus. It's typically given in a series of five shots to infants and toddlers at two months, four months, six months, 15-18 months, and 4-6 years of age to develop immunity. Hepatitis vaccines, including Hepatitis A and B, are administered to prevent these viral infections that primarily affect the liver. Both vaccines are usually given as two shots, with the second dose delivered six months after the first. The Human Papillomavirus (HPV) vaccine is given to protect against the viral infection known to cause certain types of cancers, such as cervical and throat cancer. It is usually given to preadolescents aged 9-14 over two doses six months apart. The influenza vaccine, typically known as the 'flu shot,' is given annually to protect against seasonal flu viruses. It's recommended for everyone over the age of 6 months, particularly those at risk of severe flu complications, such as the elderly and people with chronic health conditions/ The Measles vaccine is commonly given as part of the measles, mumps, and rubella (MMR) vaccine, and administered in a series of two doses at 12-15 months and 4-6 years of age to protect against these highly contagious viral diseases. The Meningococcal vaccine is given to protect against bacterial infections that can lead to severe conditions such as meningitis and bloodstream infections. It's usually administered to preteens and teenagers and includes a booster shot in the late teens. Mumps and Rubella vaccines are typically given as part of the MMR vaccine and measles. Two doses are given in childhood to ensure immunity. However, adults without immunity or vaccination records may also require vaccination. The Pneumococcal vaccine protects against types of bacteria that cause pneumococcal disease, including pneumonia, meningitis, and bloodstream infections, for all children under the age of 2, adults 65 years and above, and individuals with specific health conditions. The Polio vaccine is given to prevent poliomyelitis, a highly infectious disease that leads to paralysis. Children typically receive four doses at two months, four months, 6-18 months, and 4-6 years. The Rotavirus vaccine protects against a viral infection provoking severe diarrhea in infants and young children. It's typically given orally in two or three doses during the first six months of life. The Varicella vaccine is administered to protect against chickenpox, a highly contagious disease. It's typically given in two doses, with the first dose at 12-15 months and the second at 4-6 years of age.

Route of administration: Increasing adoption of oral vaccines for longer-lasting immune responses

Intramuscular and Subcutaneous administrations are the most common methods for vaccine delivery. This route allows the vaccine to be retained in the muscle or beneath the skin, promoting an efficient immune response. The oral route of vaccine administration is a popular alternative often used when needle-based administration is not preferred or practical. Oral vaccines, such as those for rotavirus, polio (OPV), and cholera, have proven effective and easy to administer. Both administration routes have unique advantages, such as swift immunity in intramuscular and subcutaneous administration and needle-free convenience with oral vaccines. However, they each have drawbacks, such as pain and needle-stick injuries from intramuscular and subcutaneous injections or restrictions due to gastrointestinal conditions for oral vaccines. Vaccine selection depends upon the individual vaccine, recipient, and healthcare environment. Advancements in non-intrusive vaccination methods are anticipated to drive industry research and partnerships.

Age Group: wider adoption of pediatric vaccine as a preventive measure owing to rising HPV vaccine usability

The adult population, considered those over the age of 18, comprises the more significant portion of the vaccine market. This group primarily requires vaccines to boost their immunity, prevent diseases, and meet the needs of travel vaccinations. The pediatric segment of the vaccine market focuses on children under the age of 18. Necessary immunizations, disease prevention, and peak medical advisory compliance primarily drive this category. While the adult vaccine market excels in prevention and maintenance, the pediatric section is fundamentally preventive.

Regional Insights

In Asia-Pacific, robust economies such as China, India, and Japan have exhibited significant growth in vaccine markets due to large population densities and high prevalence of infectious diseases, necessitating comprehensive immunization drives. There's a high need for vaccines in the Americas, comprising countries such as the United States and Canada, owing to the demographic makeup and an expansive public health infrastructure. Significant investments in research and development (R&D) of vaccines, recent patents, and initiatives further fuel the growth. The EMEA region, with diverse economic landscapes, displays varying consumer behavior. The European Union, with well-funded health systems, necessitates extensive immunization programs. The Middle East and Africa possess a significant potential for market growth. Initiatives such as the collaboration between the Serum Institute of India and the Africa Vaccine Acquisition Trust in 2022 to supply COVID-19 vaccines are pivotal changes reshaping this landscape.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Vaccines Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Vaccines Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Vaccines Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Astellas Pharma Inc., AstraZeneca PLC, Bavarian Nordic A/S, Bharat Biotech Ltd., Biological E. Limited, Chongqing Zhifei Biological Products Co.,Ltd., CSL Limited, CureVac SE, Daiichi Sankyo Co., Ltd., Emergent BioSolutions Inc., Gennova Biopharmaceuticals Limited, GlaxoSmithKline PLC, Inovio Pharmaceuticals, Inc., Johnson & Johnson Services, Inc., Merck KGaA, Mitsubishi Chemical Group Corporation, Moderna Inc., Novavax, Inc., Pfizer Inc., Sanofi Group, Serum Institute of India Pvt. Ltd., Sinovac Biotech Ltd., Takeda Pharmaceutical Company Limited, and Zydus Lifesciences Limited.

Market Segmentation & Coverage

This research report categorizes the Vaccines Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Type
  • Monovalent Vaccine
  • Multivalent Vaccine

• Technology Type
  • Inactivated Vaccines
  • Live-Attenuated Vaccines
  • Messenger RNA (mRNA) Vaccines
  • Subunit, Recombinant, Polysaccharide, & Conjugate Vaccines
  • Toxoid Vaccines
  • Viral Vector Vaccines

• Indication
  • DPT
  • Hepatitis
  • Human Papillomavirus
  • Influenza
  • Measles
  • Meningococcal Disease
  • Mumps & Rubella
  • Pneumococcal Disease
  • Polio
  • Rotavirus
  • Varicella

• Route of administration
  • Intramuscular & Subcutaneous
  • Oral

• Age Group
  • Adults
  • Pediatric

• Region
  • Americas
    • Argentina
    • Brazil
    • Canada
    • Mexico
    • United States
      • California
      • Florida
      • Illinois
      • New York
      • Ohio
      • Pennsylvania
      • Texas
  • Asia-Pacific
    • Australia
    • China
    • India
    • Indonesia
    • Japan
    • Malaysia
    • Philippines
    • Singapore
    • South Korea
    • Taiwan
    • Thailand
    • Vietnam

• Europe, Middle East & Africa
  • Denmark
  • Egypt
  • Finland
  • France
  • Germany
  • Israel
  • Italy
  • Netherlands
  • Nigeria
  • Norway
  • Poland
  • Qatar
  • Russia
  • Saudi Arabia
  • South Africa
  • Spain
  • Sweden
  • Switzerland
  • Turkey
  • United Arab Emirates
  • United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.

2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.

3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.

4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.

5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Vaccines Market?

2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Vaccines Market?

3. What are the technology trends and regulatory frameworks in the Vaccines Market?

4. What is the market share of the leading vendors in the Vaccines Market?

5. Which modes and strategic moves are suitable for entering the Vaccines Market?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Rising incidence of infectious diseases globally
    • 5.1.1.2. Favorable government initiatives and policies for vaccine development
    • 5.1.1.3. Growing focus on immunization across the world
  • 5.1.2. Restraints
    • 5.1.2.1. High development costs, lengthy testing and approval processes
  • 5.1.3. Opportunities
    • 5.1.3.1. Integration of adjuvants in vaccines and development of therapeutic vaccines
    • 5.1.3.2. Growth in the contract manufacturing of the vaccines
  • 5.1.4. Challenges
    • 5.1.4.1. Issues over product recalls and inaccessibility in few regions
• 5.2. Market Segmentation Analysis
  • 5.2.1. Type: Significant preference for monovalent vaccines for specific disease prevention
  • 5.2.2. Technology Type: Rising development in the conjugate vaccines as an viable alternative
  • 5.2.3. Indication: Growing need for DPT vaccine for protection against serious respiratory ailments
  • 5.2.4. Route of administration: Increasing adoption of oral vaccines for longer-lasting immune responses
  • 5.2.5. Age Group: wider adoption of pediatric vaccine as a preventive measure owing to rising HPV vaccine usability
• 5.3. Market Disruption Analysis
• 5.4. Porter's Five Forces Analysis
  • 5.4.1. Threat of New Entrants
  • 5.4.2. Threat of Substitutes
  • 5.4.3. Bargaining Power of Customers
  • 5.4.4. Bargaining Power of Suppliers
  • 5.4.5. Industry Rivalry
• 5.5. Value Chain & Critical Path Analysis
• 5.6. Pricing Analysis
• 5.7. Technology Analysis
• 5.8. Patent Analysis
• 5.9. Trade Analysis
• 5.10. Regulatory Framework Analysis

6. Vaccines Market, by Type

• 6.1. Introduction
• 6.2. Monovalent Vaccine
• 6.3. Multivalent Vaccine

7. Vaccines Market, by Technology Type

• 7.1. Introduction
• 7.2. Inactivated Vaccines
• 7.3. Live-Attenuated Vaccines
• 7.4. Messenger RNA (mRNA) Vaccines
• 7.5. Subunit, Recombinant, Polysaccharide, & Conjugate Vaccines
• 7.6. Toxoid Vaccines
• 7.7. Viral Vector Vaccines

8. Vaccines Market, by Indication

• 8.1. Introduction
• 8.2. DPT
• 8.3. Hepatitis
• 8.4. Human Papillomavirus
• 8.5. Influenza
• 8.6. Measles
• 8.7. Meningococcal Disease
• 8.8. Mumps & Rubella
• 8.9. Pneumococcal Disease
• 8.10. Polio
• 8.11. Rotavirus
• 8.12. Varicella

9. Vaccines Market, by Route of administration

• 9.1. Introduction
• 9.2. Intramuscular & Subcutaneous
• 9.3. Oral

10. Vaccines Market, by Age Group

• 10.1. Introduction
• 10.2. Adults
• 10.3. Pediatric

11. Americas Vaccines Market

• 11.1. Introduction
• 11.2. Argentina
• 11.3. Brazil
• 11.4. Canada
• 11.5. Mexico
• 11.6. United States

12. Asia-Pacific Vaccines Market

• 12.1. Introduction
• 12.2. Australia
• 12.3. China
• 12.4. India
• 12.5. Indonesia
• 12.6. Japan
• 12.7. Malaysia
• 12.8. Philippines
• 12.9. Singapore
• 12.10. South Korea
• 12.11. Taiwan
• 12.12. Thailand
• 12.13. Vietnam

13. Europe, Middle East & Africa Vaccines Market

• 13.1. Introduction
• 13.2. Denmark
• 13.3. Egypt
• 13.4. Finland
• 13.5. France
• 13.6. Germany
• 13.7. Israel
• 13.8. Italy
• 13.9. Netherlands
• 13.10. Nigeria
• 13.11. Norway
• 13.12. Poland
• 13.13. Qatar
• 13.14. Russia
• 13.15. Saudi Arabia
• 13.16. South Africa
• 13.17. Spain
• 13.18. Sweden
• 13.19. Switzerland
• 13.20. Turkey
• 13.21. United Arab Emirates
• 13.22. United Kingdom

14. Competitive Landscape

• 14.1. Market Share Analysis, 2023
• 14.2. FPNV Positioning Matrix, 2023
• 14.3. Competitive Scenario Analysis
  • 14.3.1. Oxford R21/Matrix-M Malaria Vaccine Receives WHO Recommendation for Use
  • 14.3.2. BioNTech and CEPI Announce Partnership to Advance mRNA Mpox Vaccine Development and Support CEPI's 100 Days Mission
  • 14.3.3. Pfizer and BioNTech Receive U.S. FDA Approval for 2023-2024 COVID-19 Vaccine
• 14.4. Strategy Analysis & Recommendation

15. Competitive Portfolio

• 15.1. Key Company Profiles
• 15.2. Key Product Portfolio